Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 30,000 shares at $136.90 ($4.1M) on 2021-01-04, disclosed to the SEC on 2021-01-05.
Open-market sale of $4.1M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |